Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Account Payables: 2015-2024

Historic Change in Account Payables for Corvus Pharmaceuticals (CRVS) over the last 10 years, with Dec 2024 value amounting to $1.1 million.

  • Corvus Pharmaceuticals' Change in Account Payables fell 276.21% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101,000, marking a year-over-year decrease of 78.46%. This contributed to the annual value of $1.1 million for FY2024, which is 334.37% up from last year.
  • As of FY2024, Corvus Pharmaceuticals' Change in Account Payables stood at $1.1 million, which was up 334.37% from -$451,000 recorded in FY2023.
  • In the past 5 years, Corvus Pharmaceuticals' Change in Account Payables ranged from a high of $1.1 million in FY2024 and a low of -$1.9 million during FY2021.
  • Its 3-year average for Change in Account Payables is $339,000, with a median of $411,000 in 2022.
  • Per our database at Business Quant, Corvus Pharmaceuticals' Change in Account Payables slumped by 286.65% in 2021 and then spiked by 334.37% in 2024.
  • Yearly analysis of 5 years shows Corvus Pharmaceuticals' Change in Account Payables stood at $1.0 million in 2020, then crashed by 286.65% to -$1.9 million in 2021, then skyrocketed by 121.61% to $411,000 in 2022, then slumped by 209.73% to -$451,000 in 2023, then skyrocketed by 334.37% to $1.1 million in 2024.